haematology

ASCT effective and well tolerated in elderly MM patients: Peter Mac study

The largest real world study of ASCT outcomes in elderly patients shows the therapy is safe and results in similar long-term outcomes as those experienced by younger patients undergoing the treatment. Investigators say ASCT eligibility for patients aged 70 years and over should be based on biological age, performance status and comorbidities, and not on ...

Already a member?

Login to keep reading.


OR
© 2021 the limbic